In the past six months, I have seen a large number of patients with intractable facial palsy and made a rough investigation of the factors for the development of this disease. The results showed that the high severity of peripheral facial palsy itself led to the poor efficacy of the treatment and the prolongation of the disease into intractable facial palsy, which accounted for more than half of the patients; secondly, patients with several underlying diseases, such as diabetes mellitus and hypertension, had poor prognosis due to certain restrictions on medication and treatment; and a considerable number of patients were not treated with hormone therapy in time at the early stage of the disease. In the third factor, there are many patients who refuse to take hormones on their own after being prescribed by the treating doctor; or they do not reduce the dosage according to the prescribed medication method and stop the medication without permission during the course of treatment, resulting in the delay of the disease. I personally believe that this situation is caused by the special characteristics of hormone drugs that make people have many misunderstandings about them, especially the multiple side effects of hormones, which make many people fearful of talking about hormones. Therefore it is still necessary to clarify again the importance of hormone therapy in the treatment of this disease. 1, it is currently believed that peripheral facial nerve palsy is a viral inflammatory autoimmune disease, which is a lesion caused by nerve edema after nesting pressure. The main effects of adrenocorticotropic hormone are anti-inflammatory, inhibit inflammatory response, reduce local edema of facial nerve, relieve the body’s response to endotoxin, relieve the violent response of connective tissue to injurious stimulants, and enhance the body’s adaptability and resistance to pathological injury. In the treatment of this disease, it plays a role in preventing the destructive and inflammation-induced fibrosis of inflammation, improving metabolism, alleviating the antigen-antibody reaction and the damage to tissue cells caused by the lesion, and winning the time to take other effective therapeutic measures, allowing the body’s natural defense mechanism to function. 2. The acute phase of peripheral facial palsy is 7-10 days, during which the disease can develop from mild to severe lesions. Even if other therapies are started during this phase, they play a smaller role than hormonal therapy in reducing the severity of the disease; in addition, it is impossible to predict which type of patients can develop into a severe type during the course of the disease, so it is recommended that all patients should use Hormonal therapy is recommended for all patients at the onset. If treatment is delayed, there is a risk of developing severe facial nerve damage and irreversible neuropathy. 3. Hormone use in large amounts over a long period of time can result in side effects and related complications. However, hormone therapy for peripheral facial nerve palsy often uses a high-dose, short-time treatment plan, which generally does not have side effects and is relatively safe to use. 4, strict control of contraindications, reasonable use of hormones can avoid the occurrence of clinical adverse events.